Evaluation of Histopathological and Prognostic Significance of Programmed Death Ligand 1 (PD-L1) Expression of Cutaneous Squamous Cell Carcinoma and Basal Cell Carcinoma

Mahmoud, Abla Sayed; Abd El-Moeze, Nadia Ahmed; Abd Alzeem, Mai Rowaey; Abd Elmaogod, Eman Ahmed

doi:10.21608/ejctr.2024.307403.1021

Evaluation of Histopathological and Prognostic Significance of Programmed Death Ligand 1 (PD-L1) Expression of Cutaneous Squamous Cell Carcinoma and Basal Cell Carcinoma

Document Type : Original articles

Authors

Pathology department, Faculty of Medicine, Beni-Suef University, Egypt

10.21608/ejctr.2024.307403.1021

Abstract

Basal cell carcinoma and Cutaneous squamous cell carcinoma are the most common malignancies in humans. Five-year survival rates of these tumors are considerably high, and classical treatment methods, such as surgery and radiotherapy, are generally sufficient. However, additional systemic treatment may be required for high-risk, locally advanced, and metastatic BCC and CSCC. PD-L1 activation plays an important role in the tumor’s avoidance of immune surveillance. PD-L1 expression has been studied in different tumor types. However, data on PD-L1 expression in BCC and CSCC are limited. The aim of this study is to evaluate the immunohistochemical expression of PD-L1 in CSCC and BCC cases and detect its relationship with other clinicopathological parameters as a prognostic factor. A total of 47 formalin fixed paraffin embedded skin biopsies of patients with CSCC (19) and BCC (28) were collected and studied immunohistochemically for PD-L1. All biopsies were scored for the PD-L1 expression in tumor cells and TILs. PD-L1expression was positive in 14 (73.7%) of the included CSCC cases, while 5 (26.3%) were negative. Score 0 was seen in 5 cases (26.3%), Score +1 was seen in 6 cases (31.6%), score +2 was seen in 8 cases (42.1%). PD-L1 score in tumor cells showing significant correlation with tumor size, PD-L1 expression in TILs and PD-L1 scores in TILs. According to 28 BCC cases, 27 (96.4%) showed negative PD-L1 expression in tumor cells while only one case (3.6%) has positive expression, however according to PD-L1 expression in TILs 11(39.3%) cases were negative but 17(60.7%) cases showed positive expression.

Keywords

Main Subjects

• Tissue

References

1. Amoils, M., Kim, J., Lee, C., Sunwoo, J. B., Colevas, A. D., Aasi, S. Z., ... & Divi, V. (2019). PD-L1 expression and tumor-infiltrating lymphocytes in high-risk and metastatic cutaneous squamous cell carcinoma. Otolaryngology–Head and Neck Surgery, 160(1), 93-99.
2. Bellmunt, J., Mullane, S. A., Werner, L., Fay, A. P., Callea, M., Leow, J., ... & Signoretti, S. (2015). Association of PD-L1 Expression on Tumor Infiltrating Mononuclear Cells and Overall Survival in Patients with Urothelial Carcinoma. Annals of Oncology, mdv009
3. Chang, J., Zhu, G. A., Cheung, C., Li, S., Kim, J., & Chang, A. L. S. (2017). Association between programmed death ligand 1 expression in patients with basal cell carcinomas and the number of treatment modalities. JAMA dermatology, 153(4), 285-290.
4. El Rebey, H., Mari, A., El Farargy, S., & Shawki, A. (2013). Nitric oxide synthase 2 expression in Egyptian squamous cell carcinoma. Egyptian Journal of Pathology, 33(2), 190-197.
5. Fania, L., Didona, D., Morese, R., Campana, I., Coco, V., Di Pietro, F. R., ... & Dellambra, E. (2020). Basal cell carcinoma: from pathophysiology to novel therapeutic approaches. Biomedicines, 8(11), 449.
6. Fayek, I. S., Rifaat, M. A., & Mohammed, D. B. (2019). Management and Clinico-Pathologic Aspects of Non-Melanoma Skin Cancer of the Head and Neck: A Retrospective Institutional Based Study at the Egyptian National Cancer Institute. Journal of Cancer Therapy, 10(10), 846-862.
7. Ferronika, P., Dhiyani, S. A., Budiarti, T., Widodo, I., Rinonce, H. T., & Anwar, S. L. (2022). Regulatory T Cells but Not Tumour-Infiltrating Lymphocytes Correlate with Tumour Invasion Depth in Basal Cell Carcinoma. Diagnostics, 12(12), 2987.
8. Fuchs, C. S. K., Ortner, V. K., Mogensen, M., Rossi, A. M., Pellacani, G., Welzel, J., ... & Sinx, K. (2022). 2021 international consensus statement on optical coherence tomography for basal cell carcinoma: image characteristics, terminology and educational needs. Journal of the European Academy of Dermatology and Venereology.
9. Gambichler, T., Gnielka, M., Rüddel, I., Stockfleth, E., Stücker, M., & Schmitz, L. (2017). Expression of PD-L1 in keratoacanthoma and different stages of progression in cutaneous squamous cell carcinoma. Cancer Immunology, Immunotherapy, 66, 1199-1204.
10. García-Pedrero, J. M., Martínez-Camblor, P., Diaz-Coto, S., Munguia-Calzada, P., Vallina-Alvarez, A., Vazquez-Lopez, F., ... & Santos-Juanes, J. (2017). Tumor programmed cell death ligand 1 expression correlates with nodal metastasis in patients with cutaneous squamous cell carcinoma of the head and neck. Journal of the American Academy of Dermatology, 77(3), 527-533.
11. Gompertz-Mattar, M., Perales, J., Sahu, A., Mondaca, S., Gonzalez, S., Uribe, P., & Navarrete-Dechent, C. (2021). Differential expression of programmed cell death ligand 1 (PD-L1) and inflammatory cells in basal cell carcinoma subtypes. Archives of Dermatological Research, 1-10.
12. Goto, H., Sugita, K., & Yamamoto, O. (2020). Expression of programmed death-ligand 1 in cutaneous squamous cell carcinoma arising in sun-exposed and nonsun-exposed skin. Indian Journal of Dermatology, 65(6), 506.
13. In, G. K., Nallagangula, A., Choi, J. S., Tachiki, L., Blackburn, M. J., Capone, S., Bollin, K. B., Reuben, D. Y., Shirai, K., Zhang-Nunes, S., Ragab, O., Terando, A., Hu, J. C., Lee, H., Bhatia, S., Chandra, S., Lutzky, J., & Gibney, G. T. (2022). Clinical activity of PD-1 inhibition in the treatment of locally advanced or metastatic basal cell carcinoma. Journal for immunotherapy of cancer, 10(5), e004839.
14. Jiang, Y., Chen, M., Nie, H., & Yuan, Y. (2019). PD-1 and PD-L1 in cancer immunotherapy: clinical implications and future considerations. Human vaccines & immunotherapeutics, 15(5), 1111-1122.
15. Kamiya, S., Kato, J., Kamiya, T., Yamashita, T., Sumikawa, Y., Hida, T., ... & Uhara, H. (2020). Association between PD‐L1 expression and lymph node metastasis in cutaneous squamous cell carcinoma. Asia‐Pacific Journal of Clinical Oncology, 16(2), e108-e112.
16. Kawaguchi, M., Kato, H., Tomita, H., Hara, A., Suzui, N., Miyazaki, T., ... & Matsuo, M. (2020). Magnetic resonance imaging findings differentiating cutaneous basal cell carcinoma from squamous cell carcinoma in the head and neck region. Korean Journal of Radiology, 21(3), 325-331.
17. Kraft, S., Gadkaree, S. K., Deschler, D. G., Lin, D. T., Hoang, M. P., & Emerick, K. S. (2020). Programmed cell death ligand‐1 and cytotoxic T cell infiltrates in metastatic cutaneous squamous cell carcinoma of the head and neck. Head & Neck, 42(11), 3226-3234.
18. Lehmer, L., Choi, F., Kraus, C., Shiu, J., de Feraudy, S., & Elsensohn, A. (2021). Histopathologic PD-L1 tumor expression and prognostic significance in nonmelanoma skin cancers: A systematic review. The American Journal of Dermatopathology, 43(5), 321-330.
19. Lipson, E. J., Lilo, M. T., Ogurtsova, A., Esandrio, J., Xu, H., Brothers, P., ... & Taube, J. M. (2017). Basal cell carcinoma: PD-L1/PD-1 checkpoint expression and tumor regression after PD-1 blockade. Journal for immunotherapy of cancer, 5, 1-5.
20. Malik, I. S., Asif, M., Bashir, N., Ara, N., Rashid, F., Din, H. U., Malik, N. S., & Bashir, A. (2022). Frequency of Expression of PD-1 and PD-L1 In Head And Neck Squamous Cell Carcinoma And their Association With Nodal Metastasis: A Cross-Sectional Study. Asian Pacific journal of cancer prevention : APJCP, 23(2), 467–473.
21. Malinga, N. Z., Siwele, S. C., Steel, H. C., Kwofie, L. L., Meyer, P. W., Smit, T., ... & Kgokolo, M. C. (2022). Systemic levels of the soluble co-inhibitory immune checkpoints, CTLA-4, LAG-3, PD-1/PD-L1 and TIM-3 are markedly increased in basal cell carcinoma. Translational Oncology, 19, 101384.
22. Roper, E., Lum, T., Palme, C. E., Ashford, B., Ch'ng, S., Ranson, M., ... & Gupta, R. (2017). PD-L1 expression predicts longer disease free survival in high risk head and neck cutaneous squamous cell carcinoma. Pathology, 49(5), 499-505.
23. Rutkowski, P., Owczarek, W., Nejc, D., Jeziorski, A., Wysocki, W. M., Słowińska, M., ... & Rudnicka, L. (2020). Skin carcinomas. Oncology in Clinical Practice, 16(4), 143-162.
24. Schaper, K., Köther, B., Hesse, K., Satzger, I., & Gutzmer, R. (2017). The pattern and clinicopathological correlates of programmed death‐ligand 1 expression in cutaneous squamous cell carcinoma. British Journal of Dermatology, 176(5), 1354-1356.‏
25. Slater, N. A., & Googe, P. B. (2016). PD‐L1 expression in cutaneous squamous cell carcinoma correlates with risk of metastasis. Journal of cutaneous pathology, 43(8), 663-670.
26. Thoreau, F., & Chudasama, V. (2021). Enabling the next steps in cancer immunotherapy: from antibody-based bispecifics to multispecifics, with an evolving role for bioconjugation chemistry. RSC Chemical Biology.
27. Varki, V., Ioffe, O. B., Bentzen, S. M., Heath, J., Cellini, A., Feliciano, J., & Zandberg, D. P. (2018). PD-L1, B7-H3, and PD-1 expression in immunocompetent vs. immunosuppressed patients with cutaneous squamous cell carcinoma. Cancer Immunology, Immunotherapy, 67, 805-814.
28. Wessely, A., Steeb, T., Leiter, U., Garbe, C., Berking, C., & Heppt, M. V. (2020). Immune checkpoint blockade in advanced cutaneous squamous cell carcinoma: what do we currently know in (2020). International Journal of Molecular Sciences, 21(23), 9300.
29. Yakobson, A., Abu Jama, A., Abu Saleh, O., Michlin, R., & Shalata, W. (2023). PD-1 Inhibitors in Elderly and Immunocompromised Patients with Advanced or Metastatic Cutaneous Squamous Cell Carcinoma. Cancers, 15(16), 4041.
30. Yülek, Ö., Batur, Ş., Özcan, K., Yol, C., & Aydın Ülgen, Ö. (2022). Relationship between PD-L1 expression and prognostic factors in high-risk cutaneous squamous and basal cell carcinoma. Bosnian journal of basic medical sciences, 22(6), 894–900.